EU Projects
The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.
ESAIC can successfully contribute expertise in, amongst other areas, communication, project and data management, survey creation and dissemination and event coordination by being a consortium member in a diverse range of projects.
EU Projects
Name
Title
Status
IMI-Pain Care
Improving the care of patients suffering from acute or chronic pain
Ended March 2023
ENVISION
Advance the innovative digital tool the Sandman.MD, a real-time & plug-and-play monitoring app, to an intelligent decision-support syst. for monitoring, prediction & treatment of COVID-19 patients in ICUs
Ended July 2023
IntelliLung
intelligent Lung Support for Mechanically Ventilated Patients in the Intensive Care Unit
Ongoing since 2022
SAFEST
Improving patient SAFEty in surgical care through STandardisation, harmonisation, and creation of learning health systems in Europe
Ongoing since 2022
COVend (IXION)
Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19
Ongoing since 2021
ENVISION
Started in 2021, the ENVISION project aims to advance an innovative digital tool called the Sandman.MD, a real-time and plug-and-play monitoring app, to an intelligent decision-support system for monitoring, predicting, and treating COVID-19 patients in ICUs. The project ended in July 2023. The final event, ‘Highway to Health, took place in Brussels in January 2023 and ESAIC provided key contacts for the attendance list as well as promoting the event on social media.
IntelliLung
Started in 2022 the IntelliLung project aims to provide intelligent lung support for mechanically ventilated patients in the intensive care unit. In 2023, ESAIC’s main task was to provide input into a survey, which was then disseminated to all ESAIC members. The survey was promoted at Euroanaesthesia 2023 and on social media. After the results were compiled, ESAIC did the basic analysis and wrote the corresponding report, which was submitted to the EU.
IMI-PAINCARE
Started in 2018, the IMI-PAINCARE project aims to improve the care of acute or chronic pain patients. The project ended in March 2023 after a final event in the parliament in Brussels in January 2023 which ESAIC attended.
SAFEST
Started in 2022 the SAFEST project aims to improve patient safety in surgical care through standardisation, harmonisation, and the creation of learning health systems in Europe. ESAIC’s primary focus in 2023 was communication and dissemination tasks, which included developing and distributing a dissemination, exploitation and communication plan (DCEP). In addition, a DCE monitoring tool and user instructions were developed and shared for all partners to collect and report all communication and dissemination activities.
COVend
Started in 2021, the COVend project aims to develop an effective therapy for mild and moderate ARDS (previously COVID-19) using the peptide FX06. The IXIO trial is a placebo-controlled, multi-national phase II/ ill study to assess safety and efficacy. Additionally, the project will utilise OMlCs technologies to study molecular profiles, investigate cytokine impact, and develop personalised decision support. A health economic evaluation will also be conducted to identify implementation barriers. ESAIC's main role in COVEND is for the IXION trial.
In 2023, the target population was changed (from COVID-19 to ARDS), and so substantial amendments were submitted to regulatory authorities and ethics committees for the 5 ESAIC sites (in 4 countries). The complex electronic Case Report Form (eCRF) was updated, and all associated study documents were amended. Extensive retraining and site management tasks also took place.
EU Projects
Together
improved health outcomes, patient safety,
environmental sustainability
for
and greater
across anaesthesiology and intensive care.